BioCardia, Inc. Common Stock · XNAS · 131 sessions on record
$1.01▼ −0.02 · −1.9%from $1.03 the session before · Sep 30, 2026 close · end of day
Open
$1.04
High
$1.04
Low
$1.01
Day's range
$0.033.3% of the previous close
VWAP
$1.02close −0.92% from it
Volume, shares
99.6K0.28× the 20-session average
Traded, $
$101.5K
Trades
423240 shares per trade
Previous close
$1.03−0.02 to the close
Market cap
$15.3Mat the close of Sep 30
Day range11% of the way up
$1.01$1.04
52-week range25% of the way up
$0.75 Jul 28$1.80 Jun 5
−44% from the high · +35% from the low
Options
No listed options on BCDA
Close $ · S&P 500 rebased to the first close126 sessions to Sep 30 · axis fixed at 4 × ATR-14 around the last close · hover or tap a session and the read beside the chart follows it
consolidated · latest filed Aug 12, 2026 · SEC filings
Profit −$1.6M in the Jun 2026 quarter, consolidated.
Last 8 quarters, consolidatedUS dollars as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, S&P 500 over the same session
Quarterly results of BCDA on the consolidated basis with the market's move on the first session after each filing
Quarter
Revenue $
Revenue YoY
Profit $
Profit YoY
EPS $
Market on the day
Jun 2026filed Aug 12
—
—
−$1.6M
—
—
▲ +5.6%S&P 500 +0.7% · +4.9 pp
Mar 2026filed Aug 12
—
—
−$2.3M
—
-0.21
▲ +5.6%S&P 500 +0.7% · +4.9 pp
Dec 2025filed Mar 24
—
—
−$2.0M
—
—
—not reached
Sep 2025filed Nov 12
—
—
−$1.5M
—
—
—not reached
Jun 2025filed Aug 12
—
—
−$2.0M
—
-0.40
▲ +5.6%S&P 500 +0.7% · +4.9 pp
Mar 2025filed Aug 12
—
—
−$2.7M
—
-0.59
▲ +5.6%S&P 500 +0.7% · +4.9 pp
Dec 2024filed Mar 26
—
—
−$2.3M
—
—
—not reached
Sep 2024filed Nov 12
—
—
−$1.7M
—
—
—not reached
By fiscal yearfiscal years as filed in the 10-K · named by the year the fiscal year ends
Financial-year results of BCDA on the consolidated basis, summed from the quarters filed
Year
Revenue $
Revenue YoY
Profit $
Profit YoY
EPS $
FY25to Dec 2025
—
—
−$8.2M
—
—
FY24to Dec 2024
—
—
−$7.9M
—
—
FY23to Dec 2023
—
—
−$11.6M
—
—
FY22to Dec 2022
—
—
−$11.9M
—
—
FY21to Dec 2021
—
—
−$12.6M
—
—
Fundamentals
consolidated · filings to Jun 2026 · close $1.01 on Sep 30
5.7 times book value, market cap $15.3M.
Valuation
Market cap
$15.3Mon Sep 30
Price to earnings
—
Trailing EPS
—
Price to book
5.7consolidated · balance sheet to Jun 2026
Book value a share
$0.18consolidated · balance sheet to Jun 2026
Debt to equity
—
Return on equity
-1,800%trailing profit over average equity · consolidated
Dividend yield
—
Price to sales
—
Shares outstanding
15.1Mon Sep 30
Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated
Revenue, trailing 12 months
—
Revenue growth, 12 months
—
Revenue 3-year CAGR
—trailing twelve months against the twelve months 3 years earlier · consolidated
Profit, trailing 12 months
−$7.3Mfour quarters to Jun 2026
Profit growth, 12 months
—
Profit 3-year CAGR
—
PeersBiological Products, (No Diagnostic Substances) · the ten largest by market cap · industry P/E needs two stocks with trailing profit and a market cap
Stocks in the industry Biological Products, (No Diagnostic Substances) with market cap, price to earnings and price to book
Biological Products, (No Diagnostic Substances) · SEC standard industrial classification
SEC CIK
925741
Sessions on record
131
Price source
End of day · delayed
Computed
1 Oct, 10:42 pm IST
OI Charts is not a registered investment adviser or broker-dealer. Prices, filings and open interest are public data and arithmetic on it, not a basis for any investment decision.